View Author
patient treatment cancer study melanoma interleukin interleukin -2 response interferon month group metastatic survival therapy tumor cell carcinoma effect result trial change phase ratio carcinoma level chapter activity baseline metastatic melanoma lymphocytes concentration sample range blood disease toxicity depression oncol antibody analysis table cytokine model number -12 8 weeks administration peg-ifn -2 b cell cancer observation combination immunotherapy 4 weeks serum side effects cycle factor peg-ifn ferritin high-dose phase ii study 6 months rt-pcr duration plasma antitumor induction stage rosenberg schedule killer protocol temozolomide prognostic receptor thyroid dysfunction high-dose interleukin -2 regimen response rates ifn-a melanoma patients
10 Most Recent Publications
|
Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18 952) and prognostic value on treatment outcome
(Article)
Bouwhuis, M.G. Collette, S. Suciu, S. Groot, E.R. de Kruit, W.H.J. Hagen, T.L.M. ten Aarden, L.A. Eggermont, A.M.M. Swaak, A.J.G. |
2011-08-01
|
|
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
(Article)
Patel, P. Suciu, S. Becker, J. Conry, R. Thompson, J.A. Hwu, W.-J. Agarwala, S.S. Engelen, K. Keilholz, U. Eggermont, A.M.M. Spatz, A. Mortier, L. Kruit, W.H.J. Robert, C. Schadendorf, D. Trefzer, U. Punt, C.J.A. Dummer, R. Davidson, N. |
2011-07-01
|
|
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models
(Article)
Vermaat, J.S. Tweel, I. van der Groenewegen, G. Giles, R.H. Mehra, N. Sleijfer, S. Haanen, J.B. Roodhart, J.M. Engwegen, J.Y. Korse, C.M. Langenberg, M.H. Kruit, W.H.J. |
2010-12-01
|
|
Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
(Article)
Eggermont, A.M.M. Bouwhuis, M.G. Kruit, W.H.J. Testori, A. Hagen, T.L.M. ten Yver, A. Xu, C. |
2010-03-01
|
|
Betere navolging van de richtlijn 'melanoom'
(Article)
Veerbeek, L. Poll-Franse, L.V. van de Bekkenk, M.W. Bergman, W. Hoekstra, H.J. Jansen-Landheer, M.L.E.A. Kruit, W.H.J. Mooi, W.J. Vries, E. de Rhee, H. van der |
2010-01-01
|
|
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)
(Article)
Fusi, A. Collette, S. Spatz, A. Eggermont, A.M.M. Keilholz, U. Busse, A. Suciu, S. Rietz, A. Santinami, M. Kruit, W.H.J. Testori, A. Punt, C.J.A. Dalgleish, A.G. |
2009-12-01
|
|
Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-a therapy
(Article)
Fekkes, D. Gool, A.R. van Bannink, M. Sleijfer, S. Kruit, W.H.J. Holt, B. van der Eggermont, A.M.M. Hengeveld, M.W. Stoter, G. |
2009-10-01
|
|
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
(Article)
Bouwhuis, M.G. Suciu, S. Hernberg, M. Spatz, A. Hagen, T.L.M. ten Hansson, J. Eggermont, A.M.M. Collette, S. Aamdal, S. Kruit, W.H.J. Bastholt, L. Stierner, U. Sals, F. Patel, P. Punt, C.J.A. |
2009-06-01
|
|
Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-α: Course and relationship with psychiatric status
(Article)
Gool, A.R. van Verkerk, R. Hengeveld, M.W. Fekkes, D. Bannink, M. Sleijfer, S. Kruit, W.H.J. Holt, B. van der Scharpé, S. Eggermont, A.M.M. Stoter, G. |
2008-10-01
|
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
(Article)
Eggermont, A.M.M. Suciu, S. Kusic, Z. Dummer, R. Hauschild, A. Musat, E. Spatz, A. Keilholz, U. Santinami, M. Testori, A. Kruit, W.H.J. Marsden, J. Punt, C.J.A. Salès, F. Gore, M. MacKie, R.M. |
2008-07-14
|
